Rubius Therapeutics, Inc. (NASDAQ:RUBY) Director Purchases $43,200.00 in Stock

Rubius Therapeutics, Inc. (NASDAQ:RUBY – Get Rating) Director David R. Epstein purchased 30,000 shares of the stock in a transaction that occurred on Thursday, April 21st. The stock was purchased at an average price of $1.44 per share, with a total value of $43,200.00. Following the acquisition, the director now directly owns 4,720,012 shares of […]

Related Keywords

Davidr Epstein , ,Morgan Stanley ,Securities Exchange Commission ,Zacks Investment Research ,Nasdaq ,Rubius Therapeutics Inc ,Baillie Gifford Co ,Jpmorgan Chase Co ,Venture Management ,Rubius Therapeutics Company Profile Get Rating ,Victory Capital Management Inc ,Rubius Therapeutics ,Get Rating ,Director David ,Exchange Commission ,World Investors ,Capital Management ,Baillie Gifford ,Investment Research ,Therapeutics Company Profile ,Nasdaq Ruby ,Ruby ,Medical ,Insider Trading ,Nsider Trades ,Stocks ,